Evidence map›Paper›PMID 42222639›Full record

ArticleGlomerular diseases

Global Treatment Patterns for Immunoglobulin A Nephropathy in Adults: Results from a Real-World Survey.

Sydney C W Tang, Dario Roccatello, Carolina Aldworth, Briana Ndife, Suparna Mallik, Aneesh Thomas George, Julia Kattlun, Mark Pletscher, Ceri Hirst, Michel Anton Kroes and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Glomerular diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sydney C W TangDivision of Nephrology, Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong SAR.
Dario RoccatelloDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Carolina AldworthUS Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Briana NdifeUS Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Suparna MallikGlobal Medical Affairs, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Aneesh Thomas GeorgeValue and Access International, Novartis Healthcare Pvt. Ltd., Hyderabad, India.
Julia KattlunGlobal Program Management, Development, Novartis Pharma AG, Basel, Switzerland.
Mark PletscherValue and Access International, Novartis Pharma AG, Basel, Switzerland.
Ceri HirstGlobal Medical Affairs, Novartis Pharmaceuticals UK Ltd., London, UK.
Michel Anton KroesValue and Access International, Novartis Pharma AG, Basel, Switzerland.
Jade Garratt-WheeldonRare Diseases Franchise, Adelphi Real World, Bollington, UK.
Emma ChattertonRare Diseases Franchise, Adelphi Real World, Bollington, UK.
Jonathan de CourcyRare Diseases Franchise, Adelphi Real World, Bollington, UK.
Richard A LafayetteDivision of Nephrology, Stanford Glomerular Disease Center, Stanford University, Stanford, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Data on global treatment patterns for immunoglobulin A nephropathy (IgAN) are limited. Herein, we describe real-world treatment in patients with IgAN in clinical practice across distinct global regions. Methods: This was a retrospective analysis of data from a cross-sectional, survey-based study of nephrologists actively managing patients with IgAN ( Results: At survey completion, mean (±standard deviation [SD]) patient age was 41.6 years (±13.7), and 57.4% were male. At diagnosis, median proteinuria was 1.8 g/day (range: 0.0-22.0), and mean (±SD) estimated glomerular filtration rate was 76.9 mL/min/1.73 m Conclusion: This survey found that despite high levels of proteinuria among patients with IgAN, nephrologists generally adhered to conservative treatment approaches, in line with international guidelines at survey completion. These findings highlight an opportunity to improve patient outcomes and quality of life through the broader adoption of emerging treatments.

Indexed as

Immunoglobulin A nephropathyObservational studyPatient-reported outcomesReal-world studyTreatment patterns

Identifiers

PMID42222639
PMCPMC13221177

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.